[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : TTX-MC138 is an antisense oligonucleotide that targets microRNA-10b, it is designed to inhibit microRNA-10b. It is being evaluated for advanced solid tumors.

                          Brand Name : TTX-MC138

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 17, 2024

                          Lead Product(s) : TTX-MC138

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank